JO
ELVN icon

John Overdeck’s Enliven Therapeutics ELVN Stock Holding History

John Overdeck’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
+22,758
New +$966K ﹤0.01% 3495
2025
Q1 		– Sell
-14,620
Closed -$329K – 3275
2024
Q4 		$329K Sell
14,620
-7,460
-34% -$193K ﹤0.01% 2709
2024
Q3 		$564K Buy
22,080
+4,843
+28% +$112K ﹤0.01% 2413
2024
Q2 		$403K Buy
+17,237
New +$363K ﹤0.01% 2463
2022
Q3 		– Sell
-29,784
Closed -$145K – 2558
2022
Q2 		$145K Sell
29,784
-31,252
-51% -$153K ﹤0.01% 2221
2022
Q1 		$459K Sell
61,036
-4,515
-7% -$29.8K ﹤0.01% 2060
2021
Q4 		$590K Buy
65,551
+3,177
+5% +$41.7K ﹤0.01% 3086
2021
Q3 		$1.02M Buy
+62,374
New +$1.3M ﹤0.01% 2601
2021
Q2 		– Sell
-12,732
Closed -$430K – 4166
2021
Q1 		$430K Buy
+12,732
New +$647K ﹤0.01% 3068

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

John Overdeck's ELVN Position: Q2 2026 in Review

John Overdeck opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 22,758 shares worth $1.15M. The stake represents ﹤0.01% of the portfolio and ranks #3495 among its holdings. This is a return to the name: John Overdeck previously reported a position in ELVN as recently as Q4 2024.

John Overdeck first reported a position in ELVN in Q1 2021 and has held it in 9 quarters since. 209 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • John Overdeck held 22,758 shares of Enliven Therapeutics worth $1.15M as of Q2 2026.
  • Enliven Therapeutics was a new John Overdeck position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3495 holding.
  • John Overdeck first reported a position in Enliven Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • 209 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.